Immunotherapy Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Cancer Vaccines

Researchers provide details of new studies and findings in the area of cancer vaccines

Study 1: The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice.

"Immunity and tumor protection in mice transgenic for human MUC.1, a glycoprotein expressed in the majority of cancers of epithelial origin in humans, were induced by vaccination with B lymphocytes genetically programmed to activate MUC.1-specific CD4 T cells. Their activation required a functional cooperation between two Th cells, one specific for a self (MUCA) and the other for a nonself T cell determinant," scientists in the United States report.

...

• View Other Issues of Immunotherapy Weekly
  
• View Other NewsRx Publications